CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations....
Phase 3
Valencia, Spain and 209 other locations
the safety and tolerability of itacitinib in combination with osimertinib in subjects with locally advanced or metastatic non-small cell lung...
Phase 1, Phase 2
Valencia, Spain and 30 other locations
over time. The third main question is to see if ELVN-002 works to shrink cancers that have HER2 genetic abnormalities, particularly non-sma ...
Phase 1
Valencia, Spain and 38 other locations
The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tole...
Phase 2
Valencia, Spain and 52 other locations
The study is focused on patients who have advanced non-small cell lung cancer (NSCLC).The aims of this study are to see how safe an...
Phase 2
Valencia, Spain and 54 other locations
type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and preliminarily assess its anti-cancer...
Phase 1, Phase 2
Valencia, Spain and 123 other locations
protein 4 \[CTLA4\] antibody \[another investigational medicinal product\]) in patients with advanced or metastasized non-small cell lung ca...
Phase 1
Valencia, Spain and 37 other locations
The main aim of this study is to:* evaluate safety and efficacy (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST 1.1\]...
Phase 2
Valencia, Comunidad Valenciana, Spain and 79 other locations
, early-stage non-small cell lung cancer....
Phase 2
Valencia, Spain and 94 other locations
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON...
Phase 1, Phase 2
Valencia, Spain and 40 other locations
Clinical trials
Research sites
Resources
Legal